Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Claim: “First, the $5 million isn't guaranteed - you need to read the Equity Purchase Agreement - OWCP has to file a S-1 and the SEC has to deem it effective - that won't happen since there is a ongoing investigation. “
“OWCP has 60 days to file a S-1.”
Then, quietly after SEC approved $OWCP S-1…
Claim Rejected itself!: “OWCP doesn't receive $5 million in one lump sum - it is in tranches”
Another one of your statements posted as fact disproven....
https://howtogrowmarijuana.com/new-marijuana-strains-from-israel/
The conversion Price is at 0.20 and 0.22.
500 shares of our new series of preferred stock designated as Series A Preferred Stock (the “Series A Preferred Shares”), which, as of April 30, 2018, were convertible into 25,000,000 shares of our common stock at a conversion price of $0.20 per share, subject to adjustment pursuant to the anti-dilution provisions of the Preferred Shares, and (ii) warrants representing the right to acquire 12,500,000 shares of our common stock at an exercise price of $0.22 per share (the “Warrants”), subject to adjustment pursuant to the anti-dilution provisions of the Warrants, for an aggregate purchase price of $5,000,000.
Claims of massive dilution are complete bs.
The conversion Price is at 0.20 and 0.22.
500 shares of our new series of preferred stock designated as Series A Preferred Stock (the “Series A Preferred Shares”), which, as of April 30, 2018, were convertible into 25,000,000 shares of our common stock at a conversion price of $0.20 per share, subject to adjustment pursuant to the anti-dilution provisions of the Preferred Shares, and (ii) warrants representing the right to acquire 12,500,000 shares of our common stock at an exercise price of $0.22 per share (the “Warrants”), subject to adjustment pursuant to the anti-dilution provisions of the Warrants, for an aggregate purchase price of $5,000,000.
Claims of massive dilution are untrue.
It's posted in this forum.
http://archive.fast-edgar.com//20180703/AV2ZR22CZ22RLTTZ2U2R2ZX2RU4TZZ22ZBA2/
Nor is it in any other part of the world...
Thanks..we'll see....
I was responding to one of your previous posts or one of your negative friends....go back and look and you'll find it...Nice that you jump on my post without verifying a thing..
Typical.
Three people selling shares for a grand total of 55k..lol
Some here make it an issue that 3 more shareholders are bailing.
How would you even know that?
I guess when you're trained at the I-gLow academy of reporting, fallacies, half truths and inaccuracies are the foundation upon which your character is built on.
OWC Pharmaceutical Research Corp. Completes First Part of Cannabis-Based Ointment Safety Study
OWC Logo (PRNewsFoto/OWC Pharmaceutical Research Corp)
NEWS PROVIDED BY
OWC Pharmaceutical Research Corp.
08:30 ET
RAMAT GAN, Israel, June 29, 2018 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, yesterday announced a successful completion of the first part of its Phase I, placebo controlled, maximal dose study (the "Psoriasis Study") to determine the safety and tolerability of topical ointment containing medical grade cannabis (the "Topical Ointment") in healthy volunteers. The study is being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center. Sheba is a university-affiliated hospital that serves as Israel's national medical center and is one of the leading integrated medical centers in the Middle East. The completed part of the study consisted of application of escalating doses of the Topical Ointment to healthy volunteers and was successfully completed with no adverse effects. After completion of the second part of this study, the company plans to initiate a Phase II clinical study to demonstrate the efficacy of Topical Ointment in treating mild to moderate psoriasis and other inflammatory skin diseases.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Mr. Mordechai Bignitz, the Chief Executive Officer of OWC commented, "We are very pleased to see the successful completion of this stage of the clinical testing program. OWC is committed to the development and validation of cannabis-based products for the treatment of debilitating and life-threatening diseases and is investing significant resources to prove that our products are both safe and efficacious. This study constitutes an important step in bringing relief to millions of people that do not currently have effective therapies for diseases such as psoriasis".
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
Mordechai Bignitz, Chief Executive Officer
OWC Pharmaceutical Research Corp.
Email: Mordechai.Bignitz@owcpharma.com
Tel: +972-(72)-260-8004
SOURCE OWC Pharmaceutical Research Corp.
First they need to know that the formulation is safe on healthy individuals..It's common sense.
Yes that is what a real abstract looks like..Owcp is not at that stage yet...what don't you understand..
As per usual for all your posts you take everything out of context and cherry pick to make your posts conform to your dementia.
I hope you go and get help or at least have someone that loves and cares about you so they can help you get help.
That was me that posted that after I spoke with Yossi Dagan.
I don't pay any attention to the whiners on this board.
In your mind only David...smh
Phase one of the study was not to test the efficacy of the drug..it was to test the safety itself...Of course you must have missed that..
They already showed in-vitro a 70 percent decrease in markers for the disease.
Now that they know there is absolutely no toxicity associated with the formulation, they move ahead with the next stage of the testing...again..you must have misunderstood.
Yes David it all makes sense..as you claim..Owcp being investigated by the Sec...Do you really believe if in fact the claims you make were even remotely true in nature that Owcp would be foolish enough to be pumping, putting out garbage 8k's and S1's...lol
You do understand that the majorty of people here don't fall for your complete bullshit.
There are far too many good people involved with this company for it to be a scam as you claim.
More than likely the only scam here is you.
CONUNDRUM
Lock them up for as long as you can...
I can go more than a year and a half....never tried longer.
NO..that 3 cents was how much the Cisco bottom line would be affected...share price would drop by .03 cents having to shell out to us because they are such a huge company...loss of price would be minimal.
Let the weak hands leave...without foresight there is nothing...to achieve greatness requires patience, fortitude and guts...that goes for both the company and the shareholders.
Long and Strong OW!
There is no such group...
Someone bought 3722 shares @ .025 off the open for a grand total of 93.02 cents...
Why?
This will not hold....more games?
Here's some of the context---->
"NeuroDerm has completely removed Zeevi from their website - she has been completely scrubbed from Neuroderm.
She is a Vet! "
IG "
well..on ihub..they show up as buys and sells..I was buying..I know there has to be a buyer for every seller and so forth...but the way the information is displayed can be confusing for calculating the demand or sell pressure.
Can someone please ask Iglow if those scientists were fired..If they were so good why did they? leave..something must be amiss!
Ask him if they are veterinarians.
So I just noticed something very interesting...When I put a buy order thru and pay the ask .022 it shows up as a buy...but when I buy and pay the bid .021 it shows up as a sell even though all three transactions were buys from my standpoint....
So relying on buy sell volume isn't accurately reflecting the demand at all.
Edward......true longs are going nowhere..those that invested and expected cha ching in a few months or a year..like yourself...should just sell and leave...
.....because you lack vision.
You change your opinion like I change my underwear..lol
I think cannabis could help calm your mind..I recommend our sublingual tablet when it becomes available soon.
Maybe I should remind you how this all started out....last February 23, 2018
You said it never happened...
Then you said you'd contact Grimes...
Wrong and never did....
Why should anyone on this board believe anything you write?
Grimes, Michael <grimesmi@SEC.GOV>
To:
hxxxx@bell.net
Feb. 23 at 2:25 p.m.
Good afternoon:
I’m an attorney within the Division of Enforcement, which is a division of the Securities and Exchange Commission that investigates possible violations of the federal securities laws. Additional information about the work of the Division of Enforcement can be found at the following Internet site: https://www.sec.gov/litigation.shtml.
The Commission’s mandate is to protect investors, and in many cases, in connection with our investigation, we will reach out to investors to get an understanding of their experiences in the market place. We are conducting an investigation In the Matter of OWC Pharmaceutical Research Corp. (HO-13159). We would very much appreciate the opportunity to speak with you about your experiences in the market place and as a shareholder of OWC Pharmaceutical Research Corp.
Please understand that this investigation is a non-public, fact-finding inquiry. We are trying to determine whether there have been any violations of the federal securities laws. The investigation and the interview do not mean that we have concluded that you or anyone else has broken the law. Also, the investigation does not mean that we have a negative opinion of any person, entity or security. Also, the enclosed SEC Form 1662 includes a List of Routine Uses of information provided to the Commission.
Again, we greatly appreciate the opportunity to speak with you. Feel free to reach out to me at your earliest convenience. My number is (202) 551-4861.
Michael Grimes, CPA
Staff Attorney | Division of Enforcement
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Email: Grimesmi@sec.gov
Phone: (202) 551-4861
Cell: (202) 322-3709
Stop with this jewish people control bs please....
Why should anyone of us refute claims that are bullshit?
You beat me to it and I see it all over the boards...
I don't know who started the thread that the fund was with Oppenheimer.
I just laughed and stayed out of it.
This is a growth fund based out of the Caymans with a good reputation.
Nothing more and nothing less.
They will offer these shares through their mutual fund to their clients.
They have stepped up and bought into OW because it fits their money management criteria of investing is small and medium microcap emerging comapanies.
That's what we are..a small microcap emerging company in the bio-pharma sector.
There is nothing to spin here. http://dgfund.com/
Discover Growth Fund is a mutual fund focused on making equity investments into small-cap and micro-cap public companies that have substantial growth potential. We seek out exceptional businesses with outstanding management.
The Fund invests at least 80% of the value of its net assets, plus any borrowings for investment purposes, in equity securities of small-cap and micro-cap companies. The Fund’s investment team employs a fundamental, bottom-up equity investment style, which is characterized by intensive, first-hand research and disciplined company evaluation.
The objective of the Discover Growth Fund strategy is to outperform the Russell 2000 Index with less risk over a full market cycle. The portfolio is comprised of smaller capitalization companies that are higher quality, innovative and leveraged to more sustainable elements of economic growth. The portfolios are broadly diversified and possess portfolio characteristics superior to the small cap equity market.
Discover Growth Fund measures quality by an absolute standard and a set of relative considerations with dynamic characteristics. Higher quality firms, those with more sustainable business models, consistent performance, robust cash flows,transparent financials, and effective management when compared to other similar companies, are most likely to produce durable benefits to our investors.
Even portfolios invested in higher quality companies are subject to a variety of risks, including the potential for volatility, security specific events or research analyst bias. Reduced volatility has inherent performance benefits for clients. Portfolio diversification can help mitigate company, industry, sector, region, and other market-specific risks. It is also an effective method to ensure the balance between analyst conviction and portfolio manager humility – a dynamic tension we believe serves our investors well. We thus seek to employ prudent diversification in all of
our strategies.
I pay no attention to the man behind the curtain...lol
Yes it is...look at some of the other emerging companies they have invested in...they obviously like what they see here....
Well now we know who the investors are!
Discover Growth Fund is a mutual fund that invests in micro-cap public companies that have substantial growth potential.
http://dgfund.com/
Retail investors cannot short pennies....fact.
I am leaving this board as my two other major holdings had huge news today and one moved more than 25%..
I no longer have time to putz around with this dreck.
I have gone all in on my two other holdings...
Good luck.
There is no such thing as FDA approval for compounding products...complete bs.
I just posted the proof....chew on that.